Aveo Looks to Brighter Future with Novartis Licensing Deal
By Heather Cartwright & Tridisha Goswami
Pharma Deals Review: Vol 2015 Issue 9 (Table of Contents)
Published: 15 Sep-2015
DOI: 10.3833/pdr.v2015.i9.2121 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In return for US$15 M upfront and the potential for more than US$300 M in milestone payments, Aveo Pharmaceuticals has granted Novartis worldwide rights to AV-380, its preclinical-stage drug candidatefor-cachexia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS